Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Clear all
Terminated Phase 3 Interventional

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

NCT01875653
View directory record Official record
Conditions
Stage IV Melanoma, Stage III Melanoma
Interventions
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC)
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

NCT01266083
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
Galinpepimut-S, GM-CSF, Montanide
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 7, 2026, 8:02 AM EDT
Active, not recruiting Phase 2 Interventional

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

NCT02502786
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
humanized anti-GD2 antibody, GM-CSF
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Months to 40 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00968253
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic Leukemia
Interventions
Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

NCT00256282
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vinorelbine, Docetaxel, Sargramostim
Drug
Lead sponsor
John P. Fruehauf
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study

NCT03769844
View directory record Official record
Conditions
Pediatric Sepsis-induced MODS
Interventions
GM-CSF
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 7, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

NCT00450008
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, thalidomide, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 7, 2026, 8:02 AM EDT
Terminated Phase 1 Interventional

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

NCT01081808
View directory record Official record
Conditions
Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions
EGFRBi-armed autologous activated T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease

NCT01041417
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Granulocyte-Macrophage Stimulating Factor (GM-CSF), Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and GM-CSF in Biliary Cancer

NCT02703714
View directory record Official record
Conditions
Biliary Cancer
Interventions
Pembrolizumab, Sargramostim
Drug
Lead sponsor
Robin Kate Kelley
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00027807
View directory record Official record
Conditions
Breast Cancer
Interventions
Aldesleukin, Sargramostim, therapeutic autologous lymphocytes
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

NCT00400517
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, thalidomide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 120 Years · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

NCT00046930
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
91
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

NCT00256243
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, GM-CSF, Trastuzumab
Drug
Lead sponsor
Rita Sanghvi, Mehta
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

NCT01827137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Galinpepimut-S, GM-CSF, Montanide, lenalidomide, bortezomib
Biological · Other · Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

NCT00477815
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
rituximab, melphalan, Stem Cell, Sargramostim (GM-CSF), 90Y-Zevalin, 111In Zevalin
Biological · Drug · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

NCT03304821
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
GM-CSF, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 85 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 7, 2026, 8:02 AM EDT
Not listed Early Phase 1 Interventional

A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis

NCT01555580
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Drug
Lead sponsor
Muscular Dystrophy Association
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 7, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00006113
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent
Biological · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 7, 2026, 8:02 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT04978727
View directory record Official record
Conditions
Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 7, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Sargramostim for Myeloid Dendritic Cell Deficiency

NCT03063242
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplant
Interventions
Sargramostim, Blood samples
Drug · Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 7, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

NCT00488592
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
Interventions
WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim), Montanide adjuvant
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 7, 2026, 8:02 AM EDT
Not listed Phase 2 Interventional

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

NCT00003181
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, sargramostim, vinblastine sulfate
Biological · Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 7, 2026, 8:02 AM EDT
Withdrawn Phase 2 Interventional

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

NCT05284214
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult
Interventions
Sargramostim, Ipilimumab-containing therapy
Biological
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 7, 2026, 8:02 AM EDT